SUBSCRIBE
SUBSCRIBE
Kate Goodwin

Kate Goodwin

Contributing Writer | News & Features

Kate Goodwin hails from a background primarily in marketing. A passion for health sciences and writing led her to the biopharma news world, and she’s never looked back. She’s been writing for BioSpace for more than two years with a focus on cutting edge research, Alzheimer’s disease and pediatrics. Her free time is filled by her husband, children, Beagles, books, crochet and creative writing. She can be reached at kate.goodwin@biospace.com.

Drug Development
Full Results from Esperion’s Cholesterol Drug Fail to Impress Investors
With the results from the CLEAR outcomes study, Esperion is poised for a major inflection in sales and is targeting blockbuster status, said CEO Sheldon Koenig on an investor call Monday.
March 6, 2023
 · 
2 min read
 · 
Kate Goodwin
Picture of MorphoSys office, image courtesy nitpic
Business
MorphoSys Cuts Pre-Clinical Programs, 17% of Staff
MorphoSys AG announced Thursday it plans to drop its pre-clinical programs and cut 17% of its workforce in an effort to extend its cash runway.
March 2, 2023
 · 
1 min read
 · 
Kate Goodwin
Courtesy of Cristina Arias/Getty Images
Business
Lilly Bets $630M on Pain Target Novartis Failed
Eli Lilly is expanding its pain management pipeline with a new asset from Belgium-based Confo Therapeutics targeting the angiotensin II type 2 receptor.
March 2, 2023
 · 
2 min read
 · 
Kate Goodwin
Catherine Stehman-Breen, CEO, Chroma Medicine/comp
Drug Development
Chroma Scores $135M for Epigenetic Editing Approach
Backed by Google Ventures, ARCH Venture Partners and more, Chroma Medicine announced the closing of a $135 million Series B financing Wednesday.
March 1, 2023
 · 
2 min read
 · 
Kate Goodwin
Courtesy of Getty Images
Business
Economic Constriction has Fallout on Investments, IPOs and Collaborations
As the macro pressures of higher rates and fear of recession build, today’s investor is increasingly risk averse. With zero-risk options offering decent returns, only the highest-quality programs will get funding.
February 28, 2023
 · 
2 min read
 · 
Kate Goodwin
Pictured: uniQure headquarters in Amsterdam
Business
After Historic Hemophilia B Approval, uniQure Targets Huntington’s and ALS
In its 2022 financial report Monday, uniQure provided updates on the progress of its Huntington’s disease and ALS programs.
February 27, 2023
 · 
1 min read
 · 
Kate Goodwin
Harold Cunningham/Getty Images
Drug Development
Novartis Culls Pliant-Partnered NASH Program in Pipeline Sweep
Novartis recently announced it is returning a Phase II-ready nonalcoholic steatohepatitis asset to Pliant. The program stemmed from a 2019 collaboration.
February 24, 2023
 · 
2 min read
 · 
Kate Goodwin
Harold Cunningham/Getty Images
Drug Development
Novartis Drops SCD Gene Therapy Program with Intellia
Novartis has abandoned its ex vivo sickle cell disease program developed using Intellia Therapeutics’ CRISPR gene editing platform, Intellia announced Thursday.
February 23, 2023
 · 
2 min read
 · 
Kate Goodwin
Nicolas Economou/NurPhoto/Getty Images
Moderna Leans into R&D as Spikevax Sales Face Drop-Off
Riding high on Spikevax sales, Moderna closed out 2022 with strong financials and a plan to invest heavily into R&D in 2023.
February 23, 2023
 · 
2 min read
 · 
Kate Goodwin
Maddie Meyer/Getty Images
Business
Moderna’s Latest Partnership Combines mRNA with Gene Editing
Life Edit’s technology will combine with Moderna’s mRNA platform to develop in vivo gene editing therapeutics against thus far undisclosed challenging genetic diseases.
February 22, 2023
 · 
2 min read
 · 
Kate Goodwin
Drug Development
FDA Approves Apellis’ Syfovre as First Treatment for Geographic Atrophy
On Friday, the FDA approved Apellis Pharmaceuticals’ Syfovre (pegcetacoplan) as the first treatment for geographic atrophy (GA), a leading cause of blindness.
February 20, 2023
 · 
2 min read
 · 
Kate Goodwin
Drug Development
Hemab Secures $135M for Neglected Bleeding Disorders
Hemab Therapeutics announced the closing of an oversubscribed Series B round to bring new treatment options for lesser-known bleeding disorders.
February 20, 2023
 · 
2 min read
 · 
Kate Goodwin
Policy
Eisai Anticipates Full Approval of Leqembi as Early as July
If Leqembi is granted priority review from the agency, full approval could come as soon as July, Ivan Cheung, chairman and CEO, Eisai Inc., told CNBC Thursday.
February 17, 2023
 · 
2 min read
 · 
Kate Goodwin
Nicolas Economou/NurPhoto/Getty Images
Drug Development
Moderna’s mRNA Flu Vaccine Effective Against A, Falls Short Against B
Moderna announced mixed interim results Thursday from a Phase III trial of mRNA seasonal flu vaccine candidate, mRNA-1010.
February 17, 2023
 · 
2 min read
 · 
Kate Goodwin
Getty Images
Business
Alnylam Vets Raise $193M to Solve Gene Therapy’s Biggest Hurdle - Delivery
Aera Therapeutics emerged from stealth mode Thursday with a platform based on the work of Feng Zhang, Ph.D. and ex-Alnylam executive Akin Akinc at the helm.
February 16, 2023
 · 
2 min read
 · 
Kate Goodwin
Load More